The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
Nov 30, 2012 | 5:30 AM EST - 

Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.

Columnist Conversations

My bad - I must have misunderstood this part of the Diary. Maybe reword (just whenever you get the chance) to ...
All great questions. Firstly, unlike most I am not self confident. I take positons based on FMV analysis and p...
Doug - I noticed you have had a conviction towards the short side. First all-in short SPY (Oct 7 11:08 am), th...
Morgan Stanley's list to buy now into earnings season: ABBV, ALLY, AMZN, CCI, FIT, GOOGL, SABR, SBNY,VRTX, SA...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.